Gpnmb peptide vaccine
Gpnmb peptide vaccine has been studied in 1 paper since 2022: none in people yet, 1 review. No study of it in people or animals has been published yet. The newest paper, Jan 28, 2022: “Antiaging Vaccines Targeting Senescent Cells”.
1 paper studies it2 findingsUpdated
What did studies of Gpnmb peptide vaccine find?
2Studies of Gpnmb peptide vaccine measured 2 outcomes; the most studied are glucose intolerance (1 study) and atherosclerotic plaque burden (1).
Glucose intolerance
downin mice1
1 study
Glucose intolerance
downin mice1
Gpnmb peptide vaccine decreases glucose intolerance in mice.
“The vaccine reduces atherosclerotic plaque burden and metabolic dysfunction such as glucose intolerance in mouse models of obesity and atherosclerosis.”
Reviewin mouse models of obesity and atherosclerosis
Antiaging Vaccines Targeting Senescent Cells
Rejuvenation research
Atherosclerotic plaque burden
downin mice1
1 study
Atherosclerotic plaque burden
downin mice1
Gpnmb peptide vaccine decreases atherosclerotic plaque burden in mice.
“The vaccine reduces atherosclerotic plaque burden and metabolic dysfunction such as glucose intolerance in mouse models of obesity and atherosclerosis.”
Reviewin mouse models of obesity and atherosclerosis
Antiaging Vaccines Targeting Senescent Cells
Rejuvenation research